Basic Information
| LncRNA/CircRNA Name | GMDS-DT |
| Synonyms | GMDS-AS1 |
| Region | GRCh38_6:2245748-2482022 |
| Ensemble | ENSG00000250903 |
| Refseq | NR_046229 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, other |
| Sample | HCC tissues and cell line (U937) |
| Expression Pattern | down-regulated |
| Function Description | The expression of GMDS-DT in liver cancer tissue was significantly lower than that in adjacent normal liver tissue (P<0.001), and was significantly associated with drinking history and metastasis (both P<0.05). The Kaplan-Meier test suggested that patients with lower expression levels of GMDS-DT in liver cancer tissue had significantly shorter disease-free survival and overall survival times after hepatectomy (P=0.028 and P=0.003, respectively). Cox regression analysis further indicated that GMDS-DT was an independent risk factor for disease-free survival and overall survival times of patients after hepatectomy (P=0.015 and P=0.001, respectively). |
| Pubmed ID | 31423008 |
| Year | 2019 |
| Title | Decreased Expression of Long Non-Coding RNA GMDS Divergent Transcript (GMDS-DT) Is a Potential Biomarker for Poor Prognosis of Hepatocellular Carcinoma |
External Links
| Links for GMDS-DT | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |